The Organ Transplant Recipient HPV and Skin Cancer Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMerete Haedersdal

About this trial

Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers. In particular, OTRs have increased risk of skin cancer and cancers caused by human papillomavirus (HPV), including cervical cancer and oropharyngeal cancer. There is currently limited knowledge on risk factors for HPV infection and skin cancer in OTRs, and limited knowledge on the natural history of HPV infection and cervical neoplasia in OTRs compared with immunocompetent controls. With a continuously increasing number of OTRs, there is a growing need to improve our understanding of the long-term reactions to immunosuppression.

The overall aim of this study is to investigate long term effects of immunosuppression on cutaneous and mucosal epithelium in Danish OTRs, including the risk of skin dysplasia and skin cancer, cervical and oral HPV infection and HPV-related dysplasia and cancer in OTRs.

This study will be designed as a prospective observational cohort study based on clinical data and data from nationwide Danish registries. A total of 600 female OTRs, 300 male OTRs and 600 female controls will be included from Danish dermatology departments.

The study aims to provide knowledge relevant for improving prevention of skin- and HPV-related cancers in OTRs, including personalized screening recommendations according to individual patient risk.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged ≥18 years

Solid organ transplantation recipients, i.e. kidney-, liver-, lung-, and heart transplant recipients

Stable immunosuppressive treatment for ≥3 months

No signs of acute graft rejection

Disqualifiers

Patients with concomitant bone marrow transplantation

Full hysterectomy

Able patients aged ≥18 years

No known immunosuppressive therapy or -condition

Trial population

OTRs attending regular skin cancer screening at the Departments of Dermatology at Bispebjerg Hospital (BBH), Gentofte University Hospital (GEH) and Zealand University Hospital Roskilde (ZUH) are eligible for inclusion in the cohort. Approximately 850 OTR patients are currently attending dermatologic screening at BBH, 400 at GEH, and 450 at ZUH. A total of 900 OTRs (300 men and 600 women) will be included. Patient inclusion will be distributed between the three dermatologic departments. An immunocompetent control group of women (n=600) will be recruited from the outpatient clinic at the Departments of Dermatology BBH, GEH and ZUH. Controls will be matched with female OTRs according to age (categories 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, ≥70 years).

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • No intervention

    Other intervention

    The study is an observational study without intervention.

Treatment groups

1,500 Participants
are divided into 3 treatment groups
Group A: Male organ transplant recipients1 intervention
Group B: Female organ transplant recipients1 intervention
Group C: Female immunocompetent controls1 intervention

Trial outcomes

Primary outcomes

1

Difference in prevalence, incidence and persistence of cervical HPV infection in female OTRs compared to immunocompetent controls.

Number of women with cervical HPV infection measured by PCR test.

Time frame
Evaluated at baseline and month 12

Secondary outcomes

1

Difference in prevalence of oral HPV infection in female OTRs compared to immunocompetent controls.

Number of women with oral HPV infection measured by PCR test.

Time frame
Evaluated at baseline
2

Correlations between lifestyle factors, clinical factors and occurrence of cervical HPV infection in female OTRs.

Lifestyle factors determined by questionnaire. Clinical factors from medical records. Number of women with cervical HPV infection measured by PCR test.

Time frame
Evaluated at baseline
3

Correlations between lifestyle factors, clinical factors and occurrence of oral HPV infection in female OTRs.

Lifestyle factors determined by questionnaire. Clinical factors from medical records. Number of women with oral HPV infection measured by PCR test.

Time frame
Evaluated at baseline
4

Difference in prevalence and incidence of HPV-related dysplasia and cancer in female OTRs compared to immunocompetent controls.

Number of women with HPV-related dysplasia and HPV-related cancer from registries using registry linkage.

Time frame
Evaluated at baseline and during up to 15 years after baseline.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Merete Haedersdal

Lead sponsor

Bispebjerg Hospital

Sponsor institution

Danish Cancer Society

Collaborator

Zealand University Hospital

Collaborator

Vejle Hospital

Collaborator

Herlev and Gentofte Hospital

Collaborator

Rigshospitalet, Denmark

Collaborator